Zrinka Schoenfeld-Ivezic
Leobendorf, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Reframing the value of reserve antibiotics: how ultra-orphan reimbursement pathways could offer fair and equitable access to new antibiotics.
Journal: Health policy OPEN
Published: February 12, 2026
A prospective, open label, multicenter, postmarket study evaluating Princess VOLUME Lidocaine for the correction of nasolabial folds.
Journal: Dermatologic therapy
Published: December 03, 2019
Long-term effectiveness of a hyaluronic acid soft tissue filler in patients with facial lipoatrophy, morphological asymmetry, or debilitating scars.
Journal: Journal of cosmetic dermatology
Published: July 22, 2019
Safety And Efficacy Of Princess® FILLER Lidocaine In The Correction Of Nasolabial Folds.
Journal: Clinical, cosmetic and investigational dermatology
Published: April 08, 2019
Safety and effectiveness of hyaluronic acid dermal filler in correction of moderate-to-severe nasolabial folds in Chinese subjects.
Journal: Clinical, cosmetic and investigational dermatology
Published: January 23, 2019
Treatment of facial lipoatrophy, morphological asymmetry, or debilitating scars with the hyaluronic acid dermal filler Princess® FILLER.
Journal: Clinical, cosmetic and investigational dermatology
Published: December 21, 2018
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.
Journal: Antimicrobial agents and chemotherapy
Published: March 18, 2016
Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.
Journal: Antimicrobial agents and chemotherapy
Published: October 29, 2014
Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
Journal: Antimicrobial agents and chemotherapy
Published: July 10, 2013
Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.
Journal: Antimicrobial agents and chemotherapy
Published: February 21, 2013
Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibiotics.
Journal: Journal of clinical microbiology
Published: July 21, 2012
Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).
Journal: The Journal of antimicrobial chemotherapy
Published: January 31, 2012
Last Updated: 09/26/2026